n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, February 20th, 2018

The QualityStocks
Daily Stock List

graphic
graphic

CytoDyn, Inc. (CYDY)

StockOodles, PennyStockScholar, Profitable Trader Authority, OTCtipReporter, SeeThruEquity Research, Stock News Now, PennyStockRumors.net, and AllPennyStocks reported earlier on CytoDyn, Inc. (CYDY), and we report on the Company today, here at the QualityStocks Daily Newsletter.

CytoDyn, Inc. is centering on developing subcutaneously delivered humanized cell-specific monoclonal antibodies (mAbs) as entry inhibitors for the treatment and prevention of Human Immunodeficiency Virus (HIV). The Company has one of the leading mAbs under development for HIV infection - PRO 140. This mAb is its novel self-injectable antibody for the treatment of HIV. PRO 140 has finished Phase 2 clinical trials with demonstrated antiviral activity in humans and is now in Phase 3. A biotechnology company, CytoDyn is headquartered in Vancouver, Washington.

PRO 140 is a humanized monoclonal antibody directed against CCR5, which is a molecular portal that HIV uses to enter cells. PRO 140 belongs to a new class of HIV/AIDS therapeutics - viral-entry inhibitors.

The intention of these are to protect healthy cells from viral infection. PRO 140 blocks the HIV co-receptor CCR5. Clinical trial results so far indicate that it does not affect the normal function of the cell.

Results from Phase 1/1b and Phase 2a human clinical trials have shown that PRO 140 can substantially decrease viral burden in people infected with HIV. A Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy.

CytoDyn’s objective is to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV. Moreover, PRO 140 has been designated a "fast track" product candidate by the Food and Drug Administration (FDA).

The Company’s research data has expanded the potential clinical indications for PRO 140 to include certain inflammatory diseases, autoimmunity, transplantation, and cancer.

CytoDyn announced earlier that the FDA granted Orphan Drug Designation (ODD) to PRO 140 for the prevention of graft versus host disease (GvHD). The designation provides the Company with a variety of incentives and benefits. This includes seven years of U.S. market exclusivity for PRO 140 in GvHD, subject to FDA approval for use in this indication.

In December 2017, CytoDyn announced that the Independent Data Monitoring Committee (IDMC) for the Company’s PRO 140 pivotal combination therapy trial completed a planned interim analysis of efficacy data of the first 40 patients. It recommended that the trial be continued as planned, with the protocol defined sample size and power to attain the primary endpoint. The Phase 2b/3 pivotal trial requires 50 patients for completion.

Today, CytoDyn reported the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy (ART) in patients failing their present HIV therapy. The trial data show a statistically significant decrease in HIV-1 RNA viral load of more than 0.5log with PRO 140 versus placebo.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn, said, “It is truly exciting that PRO 140 surpassed the one-week viral load reduction endpoint in what is certainly our most significant clinical trial result to date for this therapeutic candidate. Given these positive results in the combination treatment setting with PRO 140 in HIV, we look forward to completing enrolment in our ongoing monotherapy trial in HIV infection.”

CytoDyn, Inc. (CYDY), closed Tuesday's trading session at $0.695, down 8.55%, on 1,602,663 volume with 370 trades. The average volume for the last 60 days is 203,611 and the stock's 52-week low/high is $0.4551/$0.79.

Inception Mining, Inc. (IMII)

PennyStocks24, Stock Commander, Streetwise Reports, Information Solutions Group, and Charms Investments LTD reported earlier on Inception Mining, Inc. (IMII), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, Inception Mining, Inc. engages in the acquisition, exploration, and development of precious metal properties - primarily gold-related. Its main target properties are those that have been the subject of historical exploration having considerable supporting data. Inception Mining has its corporate headquarters in Salt Lake City, Utah. Clavo Rico Ltd. is the Company’s wholly-owned subsidiary.

In August of 2014, Inception Mining announced that it entered into an Ore Processing Agreement with New Jersey Mill Joint Venture (NJ Mill), a floatation mill, which can process 360 metric tonnes daily. The mill is in Kellogg, Idaho. NJ Mill will process Inception Mining's bulk samples.

Inception Mining holds interest in the U.P. and Burlington Gold Mine. This includes two Federal patented mining claims in the County of Lemhi, Northwest of Salmon, Idaho. The U.P. and Burlington Mine is within the Salmon National Forest. The mine is considered to be within the Eureka Mining District.

The Company closed the merger with Clavo Rico Ltd. It assumed management control of its principal operation, the Cerros Del Sur operation in Honduras, Central America. Clavo Rico has main operations in Honduras. Clavo Rico operates two subsidiaries and holds other mining concessions.

In August of 2015, Inception Mining assumed management control of Cerros Del Sur, the mine operator of the Clavo Rico operation. The mine and operating entity are wholly-owned by Clavo Rico Ltd. Inception Mining’s main mine is located on the 200 hectare Clavo Rico Concession, in southern Honduras.

The Cerros del Sur operation continues to make improvements in operations and recovery, along with growing its ore resources. Mine management has secured more mineable properties on its concession. Several adjacent landowners have placed the surface rights of their lands under contract with the mine.

In October 2017, Inception Mining announced the completion of the expansion project at its Clavo Rico Project. The processing capacity of excavation, hauling, and crushing facilities was increased to 500 -750 tpd. Also, stacking capacity of the leach pad was increased from 400,000 tonnes to greater than 750,000 tonnes.

Also in October, Inception Mining announced that it entered into a Joint Venture (JV) Agreement with Corpus Mining and Exploration Ltd., a company domiciled in the Turks and Caicos. The JV will result in the creation of a new company, Corpus Gold LLC. As part of this JV Agreement, Inception Mining will direct and supervise all exploration, drilling, and evaluation initiatives on the Concession.

Inception Mining states that it has positioned the Company to be diverse in its projects, agile in the marketplace, and also efficient in its operations. Mr. Trent D’Ambrosio said, “We plan to expand through a slow, but deliberate and cost-effective model that will produce sustainable and profitable operations for many years to come.”

Inception Mining, Inc. (IMII), closed Tuesday's trading session at $0.28, up 7.28%, on 1,359 volume with 9 trades. The average volume for the last 60 days is 2,200 and the stock's 52-week low/high is $0.1125/$0.45.

Kush Bottles, Inc. (KSHB)

Stock News Now, The Street, StreetAuthority Daily, CFN Media Group, Promotion Stock Secrets, and SmallCapVoice reported on Kush Bottles, Inc. (KSHB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kush Bottles, Inc. is a sales and distribution platform that offers packaging, supplies, vaporizers, accessories, and branding solutions for the regulated cannabis industry. The Company provides certified child-resistant and custom-branded solutions in all States that permit medical or recreational cannabis use. Kush Bottles is the only marijuana packaging company with numerous full-service facilities across the United States. The Company has its headquarters and California fulfillment center in Santa Ana, California.

Kush Bottles acquired CMP Wellness, LLC (Los Angeles, California) last year. CMP is a privately held distributor of vaporizers, cartridges, and accessories. The Company also acquired the web domain Roll-uh-Bowl.com. This is an online distribution platform for retail sales of collapsible and unbreakable medical-grade silicone water pipes.

Kush Bottles provides pop top bottles; child resistant exit, paper exit, and foil barrier bags; tubes; and polystyrene, polypropylene, or silicone containers to urban farmers, greenhouse growers, and medical and recreational cannabis dispensaries. The Company concentrates on providing the highest quality medical and food grade packaging. In addition, Kush Bottles concentrates on choosing products that are environmentally friendly and manufactured within the United States.

Kush Bottles now regularly services more than 4,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. In addition, the Company has opened a new Product Development and Genomics Lab in San Diego, California to produce unique terpene formulations.

Kush Bottles has launched the marijuana industry's first online system. The system enables customers to design custom-branded packaging solutions. The tool makes it easier for customers to place orders. The expectation is that this will lead to a higher conversion rate and a better Return on Investment (ROI).

Kush Bottles has launched a Food and Drug Administration (FDA) compliant Kush Canister™ to safely and securely store cannabis products for resale purposes. The canister can fit just over one ounce of cannabis flower. The canister has a certified child resistant push-top to comply with regulations in the States that require child resistant packaging.

This month, Kush Bottles announced it was chosen by Future Farm Technologies, Inc. (FFRMF) to develop a set of customized packaging and comprehensive compliance solutions to support its expansion into new territories. Kush Bottles will support Future Farm's expansion. It will also provide branded packaging solutions to ensure Future Farm maintains compliance with State-level regulations at all times.

Future Farm is promptly expanding its footprint in the cannabis and hemp sectors across the nation. Its emphasis is on California, Massachusetts, Maine, Florida and Puerto Rico.

Also this month, Kush Bottles announced that it entered into a strategic partnership with a top cannabis ancillary fund, Merida Capital Partners. Kush has received a $6 million equity investment from Merida to speed up its near and long-term growth strategy. Kush Bottles’ plan is to use the proceeds to expand its product portfolio, build new distribution channels and penetrate new legalized markets.

Kush Bottles, Inc. (KSHB), closed Tuesday's trading session at $5.57, up 0.36%, on 234,131 volume with 656 trades. The average volume for the last 60 days is 671,912 and the stock's 52-week low/high is $1.61/$8.51.

Organigram Holdings, Inc. (OGRMF)

CFN Media Group, InvestorPlace, Wealth Daily, Cannabis Financial Network News, and Money Morning reported earlier on Organigram Holdings, Inc. (OGRMF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Organigram Holdings, Inc.’s concentration is on producing the highest quality, condition specific medical marijuana for patients in Canada. Its wholly-owned subsidiary, Organigram, Inc., is a licensed producer of medical marijuana in Canada. Organigram’s head office, production facility, and Research and Development (R&D) are in Moncton, New Brunswick. The Company lists on the OTCQB.

Organigram provides a diverse assortment of genetics and product types. These cater to the individual needs of each and every client. The Company offers a reliable supply of premier quality, industry-leading strains to match individuals’ personal needs.

Organigram has collaborations with healthcare experts and academic institutions. It invests in medical education, outreach, and research for the use of cannabinoids as a first line of treatment.

Organigram Holdings is regulated by the Access to Cannabis for Medical Purposes Regulations (ACMPR). All of its products are manufactured under strict controls and in conformance with the Good Production Practices of the MMPR, and the security directives as defined by the Office of Controlled Substances. All products are lab tested before packaging and sale.

The Company is undergoing a production-facility expansion. This expansion will more than triple the size of Organigram’s operations. The multi-million-dollar project will meet the increasing needs of its medical patient base, as well as prepare Organigram for the legal, adult-recreational marijuana market. The highlights of the Company’s plans include the addition of around 140 new employees by the end of 2018.

Furthermore, plans include a production-capacity increase from about 5,200 kilograms (kg) annually to greater than 25,000 kg annually. Plans additionally include the acquisition of a third building at 55 English Drive for future expansion, next to the present campus.

Organigram has begun the process for re-certification as an organic producer of cannabis in Canada with ECOCERT Canada. As part of the process, Organigram submitted a complete action plan to ECOCERT Canada, outlining its approach to the growing and segregation of both product lines. The design of the plan is to ensure the integrity of organic products within its facility, and was approved by ECOCERT Canada in September 2017. ECOCERT Canada is part of the Ecocert group, one of the largest organic certification organizations globally.

In late January, Organigram Holdings announced financial results for Fiscal Q1 of 2018 ending November 30, 2017. Organigram sold roughly 195,000 grams of dried flower in Q1 2018 versus roughly 187,000 in Q4 2017 and approximately 260,000 in Q1 2017 respectively.

The Company reported its highest quarterly Net Sales to date. Net Sales increased to $2.7 million in Q1 2018. This is up from $2.1 million in Q4 2017, and up from $2.2 million in Q1 2017. Organigram reported a Net Loss and Comprehensive Loss of $1.4 million for Q1 2018 versus a Net Loss of $2 million in Q4 2017 and $0.8 million in Q1 2017.

This month, Organigram announced that it received an expanded cultivation license from Health Canada related to its earlier announced Phase 2 expansion. The scope of the amendment includes approval of the entire perimeter of the expanded facility, around 150,000 sq. ft., and approval of the first 10 of the Company’s new 23 three-level cultivation rooms. It also includes approval of improved functional design to facilitate production. This includes a custom designed potting room and an automated feed and watering system.

Organigram Holdings, Inc. (OGRMF), closed Tuesday's trading session at $3.4272, up 6.00%, on 334,062 volume with 839 trades. The average volume for the last 60 days is 604,215 and the stock's 52-week low/high is $1.35/$4.56.

OWC Pharmaceutical Research Corp. (OWCP)

CFN Media Group, Promotion Stock Secrets, and Cannabis Financial Network News reported previously on OWC Pharmaceutical Research Corp. (OWCP), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OWC Pharmaceutical Research Corp. involves in the research and development (R&D) of cannabis-based medical products. It provides medical products for the treatment of diverse medical conditions and/or diseases. These include multiple myeloma, psoriasis, PTSD, and migraines; as well as delivery systems. One World Cannabis Ltd. is a wholly-owned subsidiary of OWC Pharmaceutical Research. OTCQB-listed, OWC Pharmaceutical Research has its headquarters in Petach Tikva, Israel.

The Company has entered into research and collaboration agreements with three of the leading research institutions in Israel. These include Sheba Academic Medical Center, one of the top academic hospitals in the Middle East.

These agreements serve as the underpinning for OWC’s clinical trials. They ensure that all of its studies have been, and will continue to be, founded on established research protocols of the U.S. Food and Drug Administration (FDA), Institutional Review Boards, and Independent Ethical Committees.&

One World Cannabis’ Research Division centers on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of varied medical conditions. Its Consulting Division’s dedication is to helping governments and companies navigate complex worldwide cannabis regulatory frameworks. A medical cannabis R&D business, all of the Company’s research takes place at foremost Israeli hospitals and scientific institutions. They are led by internationally distinguished investigators.

OWC Pharmaceutical Research has completed the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The technology behind the tablet is protected. It provides for the ingestion of almost any dosage of medical cannabis with a sublingual delivery mechanism, where the compounds are absorbed directly into the patient's blood by way of oral epithelial tissue.

OWC Pharmaceutical Research has received the first ever Institutional Review Board (IRB) approval to conduct a safety study for a cannabis-based topical cream with greater than 3 percent THC. The Company is conducting a safety study (FDA Phase 1 equivalent) in one of the largest academic hospitals in Israel.

OWC has also completed the development of an orally disintegrating tablet, an important new delivery form. In addition, the Company’s topical cream for Psoriasis is ready for market.

This past December, OWC Pharmaceutical Research received a new permit from the Israel Medical Cannabis Agency (MCA) to go on with the safety study of the Company’s oral disintegrating tablet. The study protocol was to be submitted to the Institutional Review Board (IRB) at a foremost Israeli academic hospital. The study is scheduled to commence in Q2 2018.

The Cannabis Tablet provides a delivery modality that avoids all the disadvantages of smoking regular tobacco products. It has no significant smell, a fixed dosage, and is user-friendly.

Today, OWC Pharmaceutical Research announced the appointment of Dr. Oron Yacoby Zeevi as the Company’s Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has over two decades of wide-ranging scientific experience with private and publicly listed companies in the biopharmaceutical industry. Dr. Yacoby Zeevi is the inventor of more than 50 issued patents and pending patents.

OWC Pharmaceutical Research Corp. (OWCP), closed Tuesday's trading session at $0.46, up 4.55%, on 1,591,612 volume with 385 trades. The average volume for the last 60 days is 1,493,732 and the stock's 52-week low/high is $0.201/$3.23.

Silver Bull Resources, Inc. (SVBL)

RedChip, Streetwise Reports, Street Insider, Wall Street Resources, Stockhouse, TopPennyStockMovers, and Stock Stars reported earlier on Silver Bull Resources, Inc. (SVBL), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Silver Bull Resources, Inc. is a mineral exploration company whose shares trade on the OTC Markets’ OTCQB. The Company’s flagship project is named "Sierra Mojada". This Project is 150 kilometers north of the city of Torreon in Coahuila, Mexico. The Project is highly prospective for silver and zinc. An exploration stage enterprise, Silver Bull Resources has its corporate headquarters in Vancouver, British Columbia.

The Sierra Mojada Project has an NI (National Instrument) 43-101 compliant measured and indicated Global resource of 58.7 million tonnes grading at 3.6 percent zinc and 50 g/t silver for 4.670 billion pounds of zinc and 90.8 million ounces of silver.

The Sierra Mojada Project is 100 percent owned and operated by Silver Bull Resources. The Sierra Mojada Project is part of a huge land package consisting of 40 mining concessions totaling 21,167 hectares (52,305 acres), positioned in an historical high-grade silver, lead, zinc mining district discovered in 1879.

The principal mineralization zone found at Sierra Mojada extends more than six kilometers in an East-West direction along the base of the Sierra Mojada Range parallel with the Sierra Mojada fault. Greater than 54 historical mine shafts lie along this strike, mining to depths of more than 200 meters. This area has not been mined with modern mining technology and processes.

Sierra Mojada has high-quality infrastructure. This infrastructure includes a railway to the site; a paved road; grid power, as well as five company-owned water wells. Sierra Mojada is an open pittable oxide deposit.

Silver Bull Resources announced this past November that it commenced an initial 3,000-meter exploration drill program using Major Drilling at the Sierra Mojada project in Coahuila.

Last month, Silver Bull Resources announced that it identified two new zones of high grade sulphide mineralization at its Sierra Mojada Project in Coahuila, Northern Mexico. The Company extended previously inaccessible historical workings 350 meters to the west of recent drilling. It identified two new sulphide zones grading up to 30.7 percent Zinc, 606 g/t Silver, 17.6 percent Lead, and 0.55 percent Copper, at the Sierra Mojada Project.

Furthermore, at the end of January, Silver Bull Resources provided results of five drill holes from its ongoing underground drill program targeting the newly discovered Sulphide Zone that sits under the earlier defined oxide zone on the Sierra Mojada Project. Highlights from the five holes include Hole T17013 – 17 meters @ 301g/t silver and 1.75 percent copper including 4 meters @ 502g/t silver and 2.14 percent copper.

Highlights also include Hole T17014 – 7.1 meters @ 163g/t silver and 0.57 percent copper and 1.7 meters @ 197g/t silver and 1.27 percent copper. The hole hit historical workings and was terminated.

Additionally, highlights include Hole T17015 – 1 meter @ 312g/t silver and 1.83 percent copper at 67 meters at the end of the hole. This hole also hit historical workings and was terminated.

Mr. Tim Barry, Silver Bull Resources’ President, Chief Executive Officer and Director, said, “We are very pleased with the continued excellent results from our underground drill program in the sulphide zone… Work is currently underway to identify drill pads to target these areas. Continued results from the drill program are expected out over the next month.”

Silver Bull Resources, Inc. (SVBL), closed Tuesday's trading session at $0.165, down 0.60%, on 787,893 volume with 74 trades. The average volume for the last 60 days is 442,681 and the stock's 52-week low/high is $0.0605/$0.234.

Cardax, Inc. (CDXI)

Zacks reported earlier on Cardax, Inc. (CDXI), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Cardax, Inc. is a development stage life sciences enterprise based in Honolulu, Hawaii. The Company dedicates primarily all its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS through targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Intellectual Property (IP) portfolio consists of 21 issued patents. These include 14 in the United States and seven in China, India, Japan, and Hong Kong. Cardax said it will continue to seek appropriate patent protection for its products in the U.S. and other selected nations. Cardax’s patents will expire between 2023 and 2028, subject to patent extensions. The Company has five patent applications pending in Europe, Canada, and Brazil.

Cardax is preparing proprietary nature-identical products and related derivatives by way of total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated. This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease.

Cardax’s initial main emphasis is its astaxanthin technologies. Astaxanthin is a strong and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects characteristic of anti-inflammatory treatments using steroids or NSAIDS (including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding). The safety and efficacy of Cardax’s product candidates have not been directly evaluated in clinical trials or confirmed by the Food and Drug Administration (FDA).

In 2014, Cardax and Capsugel entered into a Collaboration Agreement for the joint development of astaxanthin products for the consumer health market utilizing Capsugel’s proprietary lipid multiparticulate (LMP) formulation technology. Capsugel’s LMP technology encapsulates dissolved or suspended active ingredients into spherical lipid matrix particles. The expectation is it will boost the oral bioavailability of astaxanthin.

Furthermore, BASF has exclusively licensed rights from Cardax. This is to develop and commercialize nature-identical astaxanthin in consumer health products. BASF will pay Cardax royalties on future net sales of such products. Moreover, Cardax can purchase nature-identical astaxanthin from BASF for consumer health applications.

Cardax’ ZanthoSyn® is the Company’s first product to help consumers safely address their inflammatory health. Cardax says that ZanthoSyn® is a physician recommended anti-inflammatory supplement for health and longevity, which features astaxanthin with optimal absorption and purity. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.

In October 2017, Cardax announced that it entered into a mutual exclusivity agreement with General Nutrition Corporation (GNC) for ZanthoSyn. The exclusivity agreement builds on Cardax’s previously announced national rollout of ZanthoSyn across GNC's greater than 3,200 U.S. corporate stores.

It now designates GNC as the exclusive "brick-and-mortar" retailer of ZanthoSyn in the U.S. The exclusivity agreement encompasses the use of ZanthoSyn as a human dietary supplement, with an initial term of two years and provides for automatic renewals. GNC is the leading specialty retailer of health, wellness, as well as performance products.

Cardax, Inc. (CDXI), closed Tuesday's trading session at $0.327, up 72.01%, on 214,763 volume with 66 trades. The average volume for the last 60 days is 82,806 and the stock's 52-week low/high is $0.07/$0.59.

Galaxy Gaming, Inc. (GLXZ)

Marketbeat, Red Chip, SmallCapVoice, TaglichBrothers, The Green Baron, FeedBlitz, and Stock Profile reported earlier on Galaxy Gaming, Inc. (GLXZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Galaxy Gaming, Inc. is the world's largest independent developer, manufacturer, and distributor of casino table games and enhanced systems. The Company develops, manufactures, and distributes innovative proprietary table games, state-of-the-art electronic wagering platforms, and enhanced bonusing systems to land-based, riverboat, cruise ships, and online casinos around the world. Galaxy Gaming has its corporate office in Las Vegas, Nevada and the Company lists on the OTC Markets Group’s OTCQB.

Galaxy Gaming has an installed base of its products on thousands of gaming tables located in hundreds of casinos. The Company sells its products chiefly through its internal sales force, to casinos throughout North America, the Caribbean, the British Isles, Europe, and Africa, and also to cruise ships and internet gaming sites worldwide.

Galaxy Gaming is expanding its international footprint via its partnership with WPT Enterprises, Inc. WPT Enterprises is the owner of the World Poker Tour.

In addition, Galaxy Gaming is the exclusive provider of SpectrumVision. This is a proprietary technology employed to detect invisible markings on playing cards.

Furthermore, by way of its iGaming partner, Games Marketing Ltd., Galaxy Gaming licenses its proprietary table games to the online gaming industry. The Company’s games can be played online at FeelTheRush.com.

This past November, Galaxy Gaming announced its results for the quarter ending September 30, 2017. For Q3 2017 in comparison to Q3 2016, Revenue grew 20 percent to $3,830K. Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) decreased 16 percent to $1,278K.

The Company had a pre-tax Loss of $6K versus pretax Income of 1,013K. It had a Net Loss of $28K versus Net Income of $662K. Balance Sheet improvements (in comparison to December 31, 2016) include Cash increasing 37 percent to $3,162K.

Total Debt (gross) decreased 12 percent to $9,846K. Stockholders’ equity rose 14 percent to $5,269K.

Mr. Todd Cravens, Galaxy Gaming’s President and Chief Executive Officer, said, “Our year-over-year revenue growth of 20.0 percent reported for the third quarter of 2017 was the highest quarterly revenue growth reported this year. As has been the case for several quarters, we have been adding staff and other resources to support this growth and our future aspirations. One of the benefits of these investments was realized in September when we received a higher level of licensing from the Nevada Gaming Commission. This licensure allows us to broaden our sales activities in Nevada and gives us a roadmap to pursue licenses in other jurisdictions….”

Galaxy Gaming, Inc. (GLXZ), closed Tuesday's trading session at $1.12, up 2.75%, on 2,500 volume with 1 trade. The average volume for the last 60 days is 9,999 and the stock's 52-week low/high is $0.56/$1.47.

NaturalShrimp, Inc. (SHMP)

SmallCapVoice, Pennystockmania, ThePennyPicks, PennyPickGains, and WallstreetSurfers reported earlier on NaturalShrimp, Inc. (SHMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, NaturalShrimp, Inc. is an international leader in aquaculture technology. The Company has developed and tested the first commercially-viable system for growing shrimp indoors. The system employs a proprietary technology to reliably produce healthy, naturally-grown shrimp weekly without the use of antibiotics or toxic chemicals. NaturalShrimp is based in Dallas, Texas.

NaturalShrimp’s production facility is outside of San Antonio, Texas. The Company’s European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and worldwide production facilities and distribution channels.

NaturalShrimp, Inc. owns 100 percent of NaturalShrimp Corporation, formed to operate in the United States and Canada, and 100 percent of NaturalShrimp Global, Inc., established to create International Joint Venture (JV) Partnerships.

NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp dependably and economically in an indoor, re-circulating, saltwater facility. Its eco-friendly, bio-secure design does not depend on ocean water. It recreates the natural ocean environment allowing for high-density production, which can be replicated anywhere globally.

The NaturalShrimp Automated Monitoring and Control system utilizes individual tank monitors to automatically control the feeding, the oxygenation, and also the temperature of each of the facility tanks independently. In addition, a facility computer, running custom software, communicates with each of the controllers and performs additional data acquisition functions that can report back to a supervisory computer from anywhere in the world.

The computer automated water controls optimize the growing conditions for the shrimp as they mature to harvest size. This provides a disease-resistant production environment.

NaturalShrimp, along with its technology partner F&T Water Solutions, LLC, has teamed with Filtertech, Inc. on manufacturing the production equipment package to initially be installed at NaturalShrimp’s La Coste facility. The proprietary equipment package is the basis of the Company’s patented technology. The equipment covers NaturalShrimp’s base process of growing healthful, naturally grown shrimp without the use of chemicals and/or antibiotics.

In essence, NaturalShrimp’s production facilities will be the aquaculture industry’s first truly eco-friendly, sustainable way of cultivating shrimp in high density environments. The Company’s closed system production methods will produce fresh, gourmet grade shrimp without the use of antibiotics, pollutants, and other chemicals or without further depleting the globe’s oceans from overfishing.

Mr. Gerald Easterling, Mr. Bill G. Williams, and Mr. Tom Untermeyer founded NaturalShrimp in 2001. Mr. Williams serves as Chairman and Chief Executive Officer. Mr. Easterling serves as President. Mr. Untermeyer serves as Chief Technology Officer.

NaturalShrimp, Inc. (SHMP), closed Tuesday's trading session at $0.1199, up 4.26%, on 200 volume with 1 trade. The average volume for the last 60 days is 38,520 and the stock's 52-week low/high is $0.065/$1.00.

DOCASA, Inc. (DCSA)

Barchart, MarketWatch, and Iconstockalerts reported on DOCASA, Inc. (DCSA), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

DOCASA, Inc. focuses on investing in the fast-growing specialty coffee market, chiefly in the United Kingdom (UK). The Company, via its subsidiary, Department of Coffee and Social Affairs Ltd. (London, England) has established and is building an award-winning, market leading UK specialty coffee shop and online retail business. Department of Coffee and Social Affairs served its first coffee in December 2010 at Leather Lane, London.

DOCASA has its corporate headquarters in Schaumburg, Illinois. The Company lists on the OTC Markets Group’s OTCQB.

During the period December 2016 through February 2017, DOCASA opened four new shops in Kingston, Whitechapel, and Bank Street in London, as well as one shop in Bristol. The Company’s stores sell proprietary coffee and related products, and also complementary food and snacks.

DOCASA is also pursuing franchising and/or licensing of its branded shops and premium product offerings outside of the UK. This is in nations where the premium coffee market is fast growing.

DOCASA, by way of its award-winning subsidiary, Department of Coffee and Social Affairs Limited, previously announced the securing of its first coffee shop site in Manchester, UK. The new site is on the ground floor of Faulkner House, which is a 25,000-sq. ft. building of serviced offices, in Manchester's Piccadilly Gardens area. The new site is the Department of Coffee and Social Affairs' flagship store and barista training hub in the northern part of England.

DOCASA, through Department of Coffee and Social Affairs Limited, has secured a new coffee shop location. This is in The Arts Theatre in London's world famous West End.

DOCASA, through Department of Coffee and Social Affairs Limited, has secured a first liquor license for its newly extended and refurbished coffee shop in London's iconic Old Spitalfields Market. The Company’s coffee shops in Central London are in premium spots with foot traffic of more than 1 million people each day.

DOCASA, via Department of Coffee and Social Affairs Limited, announced in August of 2017 the launch in the United States of its award-winning specialty coffee shops, securing its first site at 800 Diversy in Chicago, Illinois.

DOCASA President & Chief Executive Officer, Ashley Lopez, said last August, "Our launch in the U.S. is a natural progression following our success and market leading position in the UK specialty coffee market. The consumption of specialty coffee is increasing as shoppers are now prioritizing experience over price in the consumption of coffee. We are the "affordable premium product" and our particular appeal to coffee lovers is reflected in everything we do. Chicago is a great place to launch into the U.S., being one of the top 5 cities in the U.S. where people of the "millennial" age live…”

DOCASA, Inc. (DCSA), closed Tuesday's trading session at $0.77, up 35.09%, on 3,167 volume with 6 trades. The average volume for the last 60 days is 912 and the stock's 52-week low/high is $0.55/$2.30.

graphic

The QualityStocks
Company Corner

graphic
graphic

First Cobalt Corp. (TSX.V:FCC) (OTCQB:FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF). Today, First Cobalt Corp. closed trading at $0.8014, off by 8.31%, on 181,233 volume with 153 trades. The stock’s average daily volume over the past 60 days is 289,044, and its 52-week low/high is $0.3148/$1.3041.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines.

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance. Disclaimer

First Cobalt Corp. Company Blog

First Cobalt Corp. News:

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) is “One to Watch”

First Cobalt Corp. (TSX.V: FCC) (OTCQB: FTSSF) Expanding Canadian Mining Interests to Meet Growing Demand

First Cobalt to Attend BMO Global Metals & Mining Conference and PDAC

Choom Holdings, Inc. (CSE:CHOO) (OTCQB:CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings, Inc. (CHOOF). Today, Choom Holdings, Inc. closed trading at $0.592, off by 2.95%, on 51,781 volume with 51 trades. The stock’s average daily volume over the past 60 days is 46,306 and its 52-week low/high is $0.1099/$0.8612.

Choom Holdings Inc. (OTCQB: CHOOF) (CSE: CHOO) has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage.

Choom Holdings, Inc. (CHOOF) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s "Choom Gang," a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with "choom," the local's term for marijuana. Choom's trademark slogans pivot off another unconventional phrase ("Say Hello to…"), bringing a heady dose of good times and good friends together as the company invites investors to "Say Hello to Choom™" as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company's first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom's initial license applications to ensure the company's readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company's character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1's revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic "Aloha" vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company's growth strategy. Get ready to "Say Hello" to opportunity, good times and good friends with Choom™. Disclaimer

Choom Holdings, Inc. Blog

Choom Holdings, Inc. News

Choom Holdings Inc. (CSE: CHOO) (OTCQB: CHOOF) is “One to Watch”

Canada’s Active Cannabis Companies Ramp Up Operations For Recreational Cannabis Legalization

Choom™ Announces Retail Dispensary Rollout Strategy

Reign Sapphire Corp. (RGNP)

The QualityStocks Daily Newsletter would like to spotlight Reign Sapphire Corp. (RGNP). Today, Reign Sapphire Corp. closed trading at $0.141, up 8.46%, on 355,307 volume with 155 trades. The stock’s average daily volume over the past 60 days is 48,199, and its 52-week low/high is $0.0519/$0.325.

Reign Sapphire Corp. (OTCQB: RGNP), a direct-to-consumer, custom and branded jewelry company operating jewelry sales, jewelry technology and blockchain divisions, today announces that it has signed an agreement with StarShop to promote ION Collection by Jen Selter.

Reign Sapphire Corp. (RGNP), is a direct-to-consumer, custom and branded jewelry company headquartered in Los Angeles, California. Reign's mission is to provide ethical and sustainable jewelry direct to the modern consumer, marketed through sophisticated digital initiatives that speak directly to individuals through social media channels and personalized promotions. The company's lean operating model ensures expenses are linked to order flow with flexible production schedules targeting just-in-time delivery, which in turn reduces or eliminates commodity risk. Reign is a member of the American Gem Trading Association, which is committed to fair trade and processing of gemstones.

Reign Sapphire Corp. owns and operates three divisions: Reign Brands, Reign Ventures and Reign Blockchain. Reign Brands features four unique, niche jewelry brands with separate social media followings:

  • Reign Sapphires: Ethically produced, millennial-targeted sapphire jewelry sourced from Australia.
  • Coordinates Collection: Custom jewelry inscribed with location coordinates commemorating life's special moments.
  • Le Bloc: Classic, customized jewelry.
  • ION Collection by Jen Selter: Athleisure jewelry brand.

Reign Ventures is the company's joint venture platform for investment and development of jewelry technology-related products.

Reign Blockchain authenticates its sapphires as conflict-free, allowing customers to wear products created by a company that shares their beliefs in human dignity and environmental stewardship. In 2018, Reign Blockchain is preparing to conduct an initial coin offering (ICO) for ReignCoin, subject to regulatory approval. ReignCoin will serve as Reign's cryptocurrency as part of a blockchain-based loyalty reward program.

The company's products are sold through a commission-based affiliate program that is supported by personalized email campaigns and promotions, celebrity promotion and gifting, digital advertising based on keyword purchases and sponsored ads, and creative publicity events and media outreach to attract maximum exposure. The successful launch of a company-wide social media influencer campaign across all its retail brands boosted Reign's Instagram, Twitter and Facebook followings by double digits within the first three weeks of going live.

Reign continues to seek out international partnerships, adding to the success it has already achieved in the Middle East, where its flagship store is in the Dubai Mall. The company recently teamed up with the original founder of its Coordinates Collection brand, Owen de Vries, who will lead its Europe and United Kingdom sales efforts. The Netherlands-based operation will proliferate Reign point-of-sales that are adapted for local language, digital marketing and customer service.

Reign Sapphire Corp. is led by president and CEO Joseph Segelman, who has also served on the board of directors since December 2014. Segelman earlier served as the Chief Executive Officer and managing director of Australian Sapphire Corporation, Shefa Mining Corporation and Spencer Lloyd & Associates. He is an experienced marketing and operations professional with over 20 years of experience in logistics and marketing, and extensive experience in the Australian mining and gem industry. He is also a director and board member of OBK (a Sydney, Australia, based charity) and a Captain (Chaplain) in the Australian Army reserves. Segelman is the author of "Take Action: Successful Australians Share their Secrets." (Lothian Books, 2004).

The company's board of advisors includes Andrea Hansen, jewelry marketing veteran and former president of the Women's Jewelry Association; Jeremy Avitan, CPA and compliance executive; Michael Lawrence corporate lawyer and litigator, Doug Cole, corporate financier and entrepreneur, Thierry Chaunu, a luxury goods executive with prior senior management roles at Chopard, Christofle and Cartier, and Pinny Gwinisch, founder of Ice.com and adjunct professor at McGill and Rutgers University. Disclaimer

Reign Sapphire Corp. Company Blog

Reign Sapphire Corp. News:

Reign Sapphire Corp. and StarShop Sign Marketing Agreement to Promote Top Social Media Influencer Brand

NetworkNewsBreaks – Why Reign Sapphire Corp. (RGNP) is “One to Watch”

Coverage Initiated for Reign Sapphire Corp. (RGNP) via NetworkNewsWire

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.4566, up 13.87%, on 104,505 volume with 47 trades. The stock’s average daily volume over the past 60 days is 265,843 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), is pleased to announce the Company and its research arm, Cannevert Therapeutics Ltd. (“CTL”), are in process of obtaining a Fairness Opinion from Davidson & Company LLP (“Davidson”) of Vancouver, Canada regarding Veritas’ planned takeover of Cannevert in the first Quarter of 2018.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Veritas Intends to Complete the 100% Takeover of Cannevert Therapeutics in Q1

Veritas’ Research Arm Cannevert Signs Clinical Research Agreement for Human Studies to Assess its Lead Cannabis Strain for Pain

Veritas Pharma Provides Comment on U.S. Attorney General Jeff Sessions Memo

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA). Today, Marijuana Company of America Inc. closed trading at $0.0308, up 5.84%, on 6,954,435 volume with 401 trades. The stock’s average daily volume over the past 60 days is 16,237,258 and its 52-week low/high is $0.0181/$0.083.

Marijuana Company of America Inc. (MCOA) was pleased to announce today the release of hempSMART™ Full Spectrum Pet Drops formulated for cats and dogs.

Marijuana Company of America Inc. (MCOA) (the "Company") are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA's CEO, founded the first marijuana company ever to trade on a US stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing expotentially and consequently the founders of MCOA have contructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can also be used to produce products that are carbon neutral or even carbon negative, like the longest, strongest natural fiber on earth, building materials that are mold, pest and fire proof, super foods and so much more for additional business opportunities. No part of the plant is left unused and the Company's overall stategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented exponential growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015's $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal and cannabis and industrial hemp sectors. The Company's business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA's strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product "hempSMART Brain," is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience. Disclaimer

Marijuana Company of America Inc. Blog

Marijuana Company of America Inc. News:

Marijuana Company of America Launches New CBD Product hempSMART™ Pet Drops

CannabisNewsBreaks – Marijuana Company of America, Inc. (MCOA) Intends to Further Diversify its Portfolio in the Booming Cannabis Industry

Marijuana Company of America, Inc. (MCOA) Executing a Strategy Aligned with Future Forces

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.0729, up 4.29%, on 5,587,830 volume with 458 trades. The stock’s average daily volume over the past 60 days is 14,002,491, and its 52-week low/high is $0.0132/$0.415.

Advanced medical software company ORHub, Inc. (OTC: ORHB) this morning announced the launch of its healthcare blockchain initiative by signing a letter of intent ("LOI") with SinglePoint, Inc. (OTCQB: SING) to design and develop optimized solutions. Per the LOI, SinglePoint will review ORHub's existing platform and deliver scalable, proprietary blockchain solutions for the company.

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsBreaks – ORHub, Inc. (ORHB) Signs LOI with Singlepoint, Inc. (SING); Launches Healthcare Blockchain Initiative

Singlepoint, Inc. (OTCQB: SING) CEO Greg Lambrecht and President Wil Ralston discuss bitcoin and cannabis industries on MoneyTV with Donald Baillargeon, 2/16

In Route to Becoming Fully Reporting, SinglePoint Up-Lists to OTCQB and adds Former Amazon GM as Additional Board Member

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $1.16, off by 2.52%, on 67,816 volume with 47 trades. The stock’s average daily volume over the past 60 days is 139,633 and its 52-week low/high is $0.20/$1.75.

ORHub, Inc. (OTC:ORHB) today announced the launch of its healthcare blockchain initiative by signing a letter of intent (“LOI”) with SinglePoint Inc. (OTCQB:SING) to design and build out go-to-market solutions.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub Launches Healthcare Blockchain Initiative to Expand Data Innovation at Point of Care

NetworkNewsAudio Announces Audio Press Release (APR) on ORHub, Now Funded for Further Market Reach with Revolutionary Software

ORHub Raises Additional $3 Million to Fund Swift Strategic Market Penetration

Epazz, Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz, Inc. (EPAZ). Today, Epazz, Inc. closed trading at $0.1475, up 9.26%, on 134,391 volume with 45 trades. The stock’s average daily volume over the past 60 days is 980,598, and its 52-week low/high is $0.0045/$0.52.

Epazz Inc. (OTC: EPAZ) announced today that the company has acquired the Play Store app Bitcoin Altcoins Tracker. The following is the link to the Bitcoin Altcoins Tracker Play Store app:
https://play.google.com/store/apps/details?id=bitcoins.altcoins.tracker&hl=en

Epazz, Inc. (EPAZ), is a leading provider of blockchain cryptocurrency mobile apps and cloud-based business software solutions that specializes in providing customized web applications to the corporate world, higher education institutions and the public sector. The company's strategic expansion into the investment fintech software space can be seen in the recent acquisition of the android app CryptoFolio, which securely tracks and manages Bitcoin and Altcoin portfolios. Epazz, Inc., which acquired the software rights, source code and user base of CryptoFolio, plans to add additional cryptocurrencies and languages to the app, along with an iOS version to attract more users.

Epazz also offers ZenaPay Bitcoin wallet, which has been downloaded more than 10,000 times since its launch on the Play Store. A subsidiary of Epazz, ZenaPay is a financial technology company that offers a unique, secure and reliable Bitcoin payment app, allowing consumers to acquire Bitcoin at the point-of-sale. The consumer can then use this digital currency to make a purchase with ease. The CryptoFolio business model provides free features to attract users and then allows users to purchase additional features from $1.99 to $5.99 each. CryptoFolio is a great add-on app for ZenaPay, and future versions of CryptoFolio will include an option to download ZenaPay.

"We are starting 2018 with ZenaPay on both major mobile apps' platforms," said Shaun Passley, PhD, CEO and founder of Epazz. "We are in the processing of developing new blockchain technology which will introduce an additional source of revenue streams for our company."

Epazz technology makes it easy to convert legacy systems into cloud business process software, for which the company then charges an annual subscription fee. Epazz has acquired 11 software companies that have converted or are in the process of converting their legacy software products to cloud software using Epazz technology. Epazz then markets the new cloud-based solutions to new and existing customers.

Epazz's unique BoxesOS™ applications can create virtual communities for enhanced communication, provide information and content for decision-making, and create a secure marketplace for any type of commerce. Epazz has also filed a provisional patent for its new blockchain smart legal contract technology that reduces fraud in business transactional contracts. The technology allows for a transactional contract to become a living contract that is tracked and traced; it also verifies that a section of terms within a contract are followed and that all parties of an agreement obey the terms of the contract.

"Blockchain-based technology is the future of the Internet," Passley said. "Epazz will add blockchain technology to all of our products in the coming months using our blockchain cloud platform, BoxesOS. The company has been working with customers to understand the best uses of blockchain, and we are excited about filing the first of many blockchain patents, with many more to come." Disclaimer

Epazz, Inc. Company Blog

Epazz, Inc. News:

Epazz ZenaPay Acquires Bitcoin Altcoins Tracker; the Next Version of CryptoFolio Will be Released on May 30, 2018

Epazz, Inc. (OTC PINK: EPAZ) Spokesman Matt Chipman Announced New Developments with the Company's Zenapay App on MoneyTV with Donald Baillargeon, 2/16

Epazz's Patent Pending Blockchain Smart Legal Contracts Technology Will be Called Cordtell and Plans to Release the Blockchain Storage Technology During the Third Quarter of 2018

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.555, off by 5.13%, on 4,387,192 volume with 1,421 trades. The stock’s average daily volume over the past 60 days is 13,787,922, and its 52-week low/high is $0.0006/$0.957.

PotNetwork Holding, Inc. (POTN) is pleased to announce that its wholly owned subsidiary, Diamond CBD, Inc., is exhibiting its 2018 product line which includes many new products available for distribution at the 37th CHAMPS Trade Show at the Las Vegas Convention Center on February 19-21, 2018.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

PotNetwork Holding’s Diamond CBD Showcases Expanded Product Line at CHAMPS Winter Show at Las Vegas Convention Center

PotNetwork Holding Successfully Launches Meds BioTech Line into New Industry Sector

Marijuana Stocks Gaining Ground After Latest Press

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0244, off by 2.40%, on 7,563,281 volume with 246 trades. The stock’s average daily volume over the past 60 days is 16,320,072, and its 52-week low/high is $0.0141/$0.16.

Global Payout, Inc. (GOHE) is pleased to announce that its majority owned subsidiary, MoneyTrac Technology, Inc. ("MTRAC" "MoneyTrac", the "Company") has appointed Mr. Jason LeBlanc to the position of Director of Business Development where he will play a critical role in supporting the continued growth and success of MTRAC in what has already been a busy and successful start to 2018 for the Company.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

MoneyTrac Technology, Inc. Appoints New Director of Business Development in Preparation for Expansion in 2018

NetworkNewsAudio Announces Audio Press Release (APR) on Global Payout, Inc. and the Promise of Blockchain-Focused Enterprises

The Missing Piece: MoneyTrac Technology Aims to Disrupt Payment Technologies in JV with GreenBox POS, a Blockchain Company

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

QualityStocks
(CDXI) +72.01%

2.

MarketBeat
(ITCC) +39.53%

3.

StockMarketWatch
(FOGO) +23.90%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251